NGR-hTNF: Additional Phase II data

Additional data from the open-label, Italian Phase II NGR014 trial in 121 chemotherapy-naïve patients with stage IIIb/IV NSCLC showed that 0.8 µg/m 2 NGR-hTNF every 3 weeks plus cisplatin and pemetrexed or gemcitabine led to similar median PFS (5.8 vs. 5.6 months), response rates (25% vs. 21%) and 1-year OS rate (53% vs. 53%) vs. cisplatin and pemetrexed alone. Median follow-up was 24.2 months. In a subgroup of patients with squamous NSCLC, NGR-hTNF plus chemotherapy significantly improved OS vs. chemotherapy alone (14.2 vs. 9.7 months, p=0.07). Additionally, in squamous patients, NGR-hTNF plus chemotherapy improved median PFS (5.6 vs. 4.3 months) and response rate (38% vs. 27%) vs. chemotherapy alone. Data were presented at the American Society of Clinical Oncology meeting in Chicago. ...